Neuberger Berman Group
CPRX

Neuberger Berman Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Neuberger Berman Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$249K Buy
10,075
+1,466
+17% +$34.9K ﹤0.01% 1917
2025
Q4 		$201K Sell
8,609
-185,445
-96% -$4.13M ﹤0.01% 1955
2025
Q3 		$3.82M Sell
194,054
-67,363
-26% -$1.39M ﹤0.01% 1021
2025
Q2 		$5.67M Buy
261,417
+56,098
+27% +$1.32M ﹤0.01% 932
2025
Q1 		$4.98M Buy
+205,319
New +$4.62M ﹤0.01% 932

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Neuberger Berman Group's CPRX Position: Q1 2026 in Review

Neuberger Berman Group increased its Catalyst Pharmaceutical (CPRX) stake by 17% in Q1 2026, buying an estimated $34.9K and bringing the position to 10,075 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Neuberger Berman Group first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.67M in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Neuberger Berman Group held 10,075 shares of Catalyst Pharmaceutical worth $249K as of Q1 2026.
  • Neuberger Berman Group bought 1,466 Catalyst Pharmaceutical shares in Q1 2026, an estimated $34.9K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1917 holding.
  • Neuberger Berman Group first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • Neuberger Berman Group's Catalyst Pharmaceutical position peaked at $5.67M in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.